Society of Family Planning clinical recommendation: Extended use of long-acting reversible contraception * , **

被引：13

作者：

Dethier, Divya ^{[1
]}

Qasba, Neena ^{[2
]}

Kaneshiro, Bliss ^{[1
]}

机构：

[1] Univ Hawaii, John A Burns Sch Med, Dept Obstet Gynecol & Womens Hlth, Honolulu, HI 96822 USA

[2] Univ Massachusetts, Chan Med Sch Baystate, Dept Obstet & Gynecol, Springfield, MA USA

来源：

CONTRACEPTION | 2022年 / 113卷

关键词：

Contraception; LARC; IUD; Implant; INTRAUTERINE SYSTEM; IMPLANT; FAILURE; EFFICACY; SAFETY; WOMEN; DEVICE; IUD;

D O I：

10.1016/j.contraception.2022.06.003

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

In this clinical recommendation, we review the evidence supporting the use of the copper intrauterine device, levonorgestrel intrauterine devices and etonogestrel subdermal implant beyond the Food and Drug Administration approved duration of use for contraception (extended use). Clinicians should discuss effectiveness as well as other clinical considerations with patients to allow them to make contraceptive decisions that support their reproductive goals and clinical needs. Extended use of long acting reversible contraception may be a safe, effective and desirable option for many patients. (c) 2022 Elsevier Inc. All rights reserved.

引用

页码：13 / 18

页数：6

共 39 条

[1]

ACOG, 2019, ACOG PRACT B, V133, P23

[2] Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant [J].

Ali, Moazzam ;

Akin, Ayse ;

Bahamondes, Luis ;

Brache, Vivian ;

Habib, Ndema ;

Landoulsi, Sihem ;

Hubacher, David .

HUMAN REPRODUCTION, 2016, 31 (11) :2491-2498

[3]

[Anonymous], 2018, Obstet Gynecol, V131, P947, DOI 10.1097/AOG.0000000000002627

[4]

[Anonymous], 2020, UCSF PILL COVID 19 L

[5]

[Anonymous], 2017, Obstet Gynecol, V130, P251

[6] Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies [J].

Apter, Dan ;

Gemzell-Danielsson, Kristina ;

Hauck, Brian ;

Rosen, Kimberly ;

Zurth, Christian .

FERTILITY AND STERILITY, 2014, 101 (06) :1656-U515

[7] TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age [J].

Bahamondes, L ;

Faundes, A ;

Sobreira-Lima, B ;

Lui, JF ;

Pecci, P ;

Matera, S .

CONTRACEPTION, 2005, 72 (05) :337-341

[8] Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil [J].

Bahamondes, Luis ;

Fernandes, Arlete ;

Valeria Bahamondes, M. ;

Juliato, Cassia T. ;

Ali, Moazzam ;

Monteiro, Ilza .

CONTRACEPTION, 2018, 97 (03) :205-209

[9]

Benson LS, 2020, Society of Family Planning interim clinical recommendations: contraceptive provision when healthcare access is restricted due to pandemic response, DOI 10.46621/UYGR2287

[10] Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial [J].

Carvalho, Nelsilene ;

Margatho, Deborah ;

Cursino, Kleber ;

Benetti-Pinto, Cristina L. ;

Bahamondes, Luis .

FERTILITY AND STERILITY, 2018, 110 (06) :1129-1136

← 1 2 3 4 →